<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169714</url>
  </required_header>
  <id_info>
    <org_study_id>B1661003</org_study_id>
    <nct_id>NCT01169714</nct_id>
  </id_info>
  <brief_title>A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.</brief_title>
  <official_title>An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to observe the safety and blood concentrations of PF-04995274 during
      and following the administration of multiple doses of PF-04995274 for a duration of 14 days,
      in healthy adult and healthy elderly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the safety and pharmacokinetics of PF-04995274 in healthy adult and healthy
      elderly subjects after multiple doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoints (Adverse events, Change from baseline in vital signs, Change from baseline in triplicate ECGs, Clinical safety laboratory, Clinical examinations, Digit Symbol Substitution Test (DSST))</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints Plasma concentration of PF 04995274 over time (eg, AUC, Cmax, Tmax, t1/2), Plasma concentration of PF 05082547 over time (eg, AUC, Cmax, Tmax, t1/2).</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic endpoint Aldosterone concentration in healthy adult subjects.</measure>
    <time_frame>Day 0 to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No secondary outcomes</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dosing Healthy Adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending Doses in Healthy Adult Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Healthy Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in Healthy Elderly volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg PF-04995274</intervention_name>
    <description>0.1 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg PF-04995274</intervention_name>
    <description>1 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg PF-04995274</intervention_name>
    <description>10 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg PF-04995274</intervention_name>
    <description>15 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg PF-04995274</intervention_name>
    <description>1.0 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg PF-04995274</intervention_name>
    <description>15 mg PF-04995274, qd, for 14 days or placebo</description>
    <arm_group_label>Dosing Healthy Elderly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Healthy adult volunteers: healthy male and/or female subjects of non child bearing
             potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no
             clinically relevant abnormalities identified by a detailed medical history, full
             physical examination, including blood pressure and heart rate measurement, 12 lead ECG
             and clinical laboratory tests.)

          -  For Healthy Elderly volunteers: healthy male and/or female subjects of non child
             bearing potential between the ages of 65 and 85 years, inclusive. Subjects must be in
             reasonably good health as determined by the investigator based on a detailed medical
             history, full physical examination (including blood pressure and pulse rate
             measurement), 12 lead ECG and clinical laboratory tests. Subjects with mild, chronic,
             stable disease (eg, controlled hypertension, non-insulin dependent diabetes,
             osteoarthritis) may be enrolled if deemed medically prudent by the investigator. In
             order to ensure an age range relevant to the Alzheimer's Disease (AD) population, no
             more than 30% of subjects enrolled in any cohort may be less than 70 years of age.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1661003&amp;StudyName=A%20Study%20To%20Observe%20Safety%20And%20Blood%20Concentrations%20Of%20PF-04995274%20During%20And%20Following%20the%20Administration%20of%20Multiple%20Doses%20Of%20PF-049952</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>multiple dose</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>healthy elderly volunteer</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

